Visiopharm strengthens its precision pathology team
Beginning October 1, 2020, Professor Mogens Vyberg is joining the team at Visiopharm as Senior Pathology Consultant, bringing his extensive experience in pathology, stain quality assurance, tissue-based research, and services to the company.
“In many ways, this is a logical next step in our long-standing scientific collaboration and our mutual passion for AI-driven Precision Pathology. We are excited that Mogens will now be able to devote some of his time to help us further accelerate the development, validation, and deployment of Precision Pathology tools for pathologists. These new products, in turn, will aid pathologists to discover, develop and validate novel companion diagnostics.”, stated Michael Grunkin, CEO of Visiopharm.
Professor Vyberg is a board-certified pathologist and has a career spanning 45 years in the field of pathology with both academic and clinical appointments at Aalborg University and Aalborg University Hospital.
In addition, Professor Vyberg has been instrumental in the area of stain quality assurance for pathology. As the co-founder and director of the international organization Nordic Immuno-histochemical Quality Control (NordiQC, www.nordiqc.org) during 2003-19 and Head of the Laboratory for Immunohistochemistry/R&D at Aalborg University Hospital, he has participated in carrying out quality assurance for more than 500 laboratories worldwide as well as the world’s leading diagnostics and pharmaceutical companies. Professor Vyberg is the author and co-author of about 130 peer-reviewed scientific papers, mostly focused on immunohistochemistry.
“It has been exciting to see how AI is starting to make a real difference to pathologists in terms of interpretive accuracy and productivity. There is still very few incorporating standardization into the algorithmic framework. This is where Visiopharm is unique with the AI-based technology for stain quality management, which is an area that we have collaborated in for several years. It will be very satisfying to help bring this technology into the world in the near future.”
Stated Professor Mogens Vyberg
Dirk Vossen, Chief Diagnostic Officer, states, “We are happy to welcome Professor Vyberg, a world-renowned pathologist, as a part of our team at Visiopharm. He will join us on our mission to improve the way cancer is diagnosed. This can only be done together with pathologists to help us understand how to apply state of the art AI technologies to solve challenging problems, such as standardization in pathology”.
Share this article
Visiopharm® is a world leader in AI-driven Digital Pathology solutions. Visiopharms’ pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in both academic institutions and the biopharmaceutical industry.
AI-based image analysis and tissue mining tools support research and drug development research worldwide, while their CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, they deliver tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in Sweden, United Kingdom, Germany, and the United States. Follow Visiopharm on LinkedIn and Twitter. For other news, visit the Visiopharm Newsroom.
